Provisional Program

Friday, 9th December, 2022
08.30 – 08.45Welcome
Jörg Fuchs and Peter Lang
08.45 – 10.00Session 1: New aspects of risk stratification
Invited speakers:

New aspects and clinical relevance of the COG neuroblastoma risk stratification
Meredith Irwin (Toronto)

New Risk stratification of neuroblastoma – common strategies between SIOPEN and GPOH
Prof. Angelika Eggert (Berlin)

How relevant is pathology for diagnosis and the decision making process in neuroblastoma risk stratification
Prof. Christian Vokuhl (Bonn)

Molecular genetics of neuroblastoma and its clinical implications
Matthias Fischer (Köln)
10.00 – 10.20Coffee Break
10.20 – 11.50 Session 2: Radiology and new aspects of diagnostic workup
Invited speakers:

Imaging in Neuroblastoma: Recommendations of the SIOPEN Radiological Committee
Irmina Sevic (Sarajevo)

18F-meta-fluorobenzylguanidine (18F-mFBG) in Neuroblastoma: Pros and Con
Bart de Keizer (Utrecht)

Combined metabolic and functional tumor volumes on PET/MRI in neuroblastoma
Maryanna Chaika (Tübingen)

Imaging of Gross Residual Disease After Surgery in Neuroblastoma: The COG Experience
Stephan Voss (Boston)

Early postoperative MRI after gross total resection: Tübingen experience and first results of a multicenter study
Sebastian Gassenmaier (Tübingen)
11.50 – 12.50Lunch Break
12.50 – 13.50Session 3: Radiation Therapy
Invited speakers:

N.N.
Beate Timmermann (Essen)

N.N.
Dr. John Lucas (Memphis)

Results and complications of Radiotherapy in NB
Mark Gaze (London)
13.50 – 14.15Coffee Break
14.15 – 15.45Session 4: Immunotherapy / Car-T-cells
Invited speakers:

Development of an Anti-GD2/B7-H3 Bispecific Antibody to Improve Tumor Targeting, Reduce Toxicity and Improve Efficacy for Neuroblastoma
Paul Sondel (Madison)

Targeting T cells and radioisotopes using bispecific antibodies
Nai-Kong Cheung (New York)

Haploidentical stem cell transplantation followed by anti-GD2 therapy in relapsed neuroblastoma
Peter Lang (Tübingen)

Long-term Infusion
Holger Lode (Greifswald)

Dissecting the Immunobiology of GD2
Robbi Majzner (Stanford)
15.45 – 16.05Coffee Break
16.05 – 17.05Session 5: Submitted Abstracts
tba
18.30Congress Dinner
Saturday, 10th December, 2022
09.00 – 09.15Key Note Lecture: History of Neuroblastoma Surgery
Mike LaQuaglia, New York
09.15 – 11.05Session 6: Surgery
Invited speakers:

Relevance of imaging and pre-treatment of HR neuroblastoma surgery
Jörg Fuchs (Tübingen)

Minimally invasive surgery for neuroblastoma: What’s new?
Sabine Sarnacki (Paris)

Surgery of ganglioneuroma
Sabine Irtan (Paris)

Complications associated with neuroblastoma surgery
Andrew Davidoff (Memphis)

Challenges in NB Surgery
Chan Hon Chui (Singapur)

The International Surgical Report Form and the complexity index for Neuroblastoma
Patrizia Dall'Igna (Bari)
11.05 – 11.25Coffee Break
11.25 – 13.15Session 7: Clinical Trials
Invited speakers:

GPOH results of Neuroblastoma studies
Thorsten Simon (Köln)

NB trials Asia
Godfrey Chan (Singapur)

High-risk neuroblastoma from the COG perspective
Rochelle Bagatell (Philadelphia)

N.N.
Maja Popovic Beck (Lausanne)

Therapeutic strategies for high-risk neuroblastoma in Europe
Ruth Ladenstein (Wien)

Management of infant Neuroblastoma
Barbara Hero (Köln)
13.15 – 14.15Lunch Break
14.15 – 15.45Session 8: Basic Research
Invited speakers:

N.N.
Steven Gilis (Boston)

Downstream signalling pathways and ALK inhibitor resistance in neuroblastoma
Johannes Schulte (Berlin)

Cellular origin and genomic evolution of childhood neuroblastoma
Dr. Frank Westermann (Heidelberg)
15.45Closing Remarks
Jörg Fuchs and Peter Lang